VANCOUVER, British Columbia, Canada—New technology from InNexus Biotechnology, known as Dynamic Cross-Linking (DXL), could be used to improve the target-binding affinity of existing monoclonal antibodies (MoAbs) as well as those in development.
The company recently announced laboratory results of its first product candidate DXL625 (CD20), a humanized anti-CD20 MoAb enhanced with DXL technology, being developed for the treatment of non-Hodgkin's lymphoma.
The DXL technique involves modifying a MoAb by adding a small peptide sequence that becomes self-recognizing when two or more MoAb molecules are in close proximity.
This self-binding property causes the modified antibodies to cluster at the target receptor, resulting in greater molecular mass on the surface of the target cell (see Figure).
Preclinical studies have shown that this higher MoAb concentration at the point of attack provides a potency advantage over conventional MoAbs in inducing cell growth inhibition, apoptosis, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity.
The company believes that by achieving a higher concentration of antibody at the antigen target, dose reduction may be possible.
